Tag: Li Ying
Han Kun, Zhong Lun act on Sino Biopharm’s USD950m LaNova buy
Han Kun and Zhong Lun advised on Sino Biopharm’s USD950m acquisition of cancer drugmaker LaNova Medicines
Han Kun and Zhong Lun advised on Sino Biopharm’s USD950m acquisition of cancer drugmaker LaNova Medicines
Follow us on LinkedIn